NCT01240980 - Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B) | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Diabetes

Interventions

DRUG

BMS-903452

Solution, Oral, 0.1 mg, once daily, 1 day

DRUG

BMS-903452

Solution, Oral, 0.6 mg, once daily, 1 day

DRUG

BMS-903452

Suspension, Oral, 3.0 mg, once daily, 1 day

DRUG

BMS-903452

Suspension, Oral, 10 mg, once daily, 1 day

DRUG

BMS-903452

Suspension, Oral, 30 mg, once daily, 1 day

DRUG

BMS-903452

Suspension, Oral, 60 mg, once daily, 1 day

DRUG

BMS-903452

Suspension, Oral, 120 mg, once daily, 1 day

DRUG

Placebo

Solution, Oral, 0 mg, once daily, 1 day

DRUG

Placebo

Suspension, Oral, 0 mg, once daily, 1 day

DRUG

BMS-903452

Suspension using crystalline form, Oral, 10 mg, once daily, 1 day

DRUG

BMS-903452

Suspension using crystalline form, Oral, 60 mg, once daily, 1 day

DRUG

Placebo

Suspension using crystalline form, Oral, 0 mg, once daily, 1 day

DRUG

BMS-903452

Solution, Oral, 0.6 mg, once daily, 1 day

DRUG

BMS-903452

Suspension, Oral, 10 mg, once daily, 1 day

DRUG

BMS-903452

Suspension, Oral, 120 mg, once daily, 1 day

Trial Locations (2)

33025

Comprehensive Phase One, Miramar

78744

Ppd Development, Lp, Austin